Clinical Trial to Evaluate the Influence of Genotype on the Pharmacokinetics/Pharmacodynamics of Clopidogrel
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study has an open-label, five-period, single-sequence design. The purpose of this study
is as follows;
1. Primary
- To evaluate the influence of genotype of drug metabolizing enzyme or transporter on
the pharmacokinetics/pharmacodynamics of clopidogrel
- To evaluate the influence of aspirin on the pharmacokinetics/pharmacodynamics of
clopidogrel
2. Secondary
- To explore the representative biomarkers for the variable
pharmacokinetics/pharmacodynamics of clopidogrel
- To evaluate the influence of genotype of drug metabolizing enzyme or transporter on
the drug-drug interactions between aspirin and clopidogrel
- To explore the representative biomarkers for the drug-drug interactions between
aspirin and clopidogrel